Thank you, Jeff. Good morning, everyone, and thanks for joining us for today’s call. With me are Dr. Nicholas Borys, Celsion’s Chief Medical Officer; and Jeffrey Church, our Chief Financial Officer from whom you just heard. As always, we are delighted to have the opportunity to update you on our progress and to answer your question. For those of you are knew the story, I’d like to give you a quick elevated pitch. Celsion’s oncology focus development stage company with two platform technologies both of which have product candidates and clinical trials. Our lead technologies are novel heat sensitive liposome that incorporates non-chemotherapeutics, it’s administered IV and one in the presence of tissue that’s been heated to just above body temperature, it’s about 40 degrees Celsius. The Celsion nanoparticle releases its payload to create a locally high concentration of the drug at target's local regional and solutions. Our first candidate on this platform is ThermoDox, ThermoDox as the name implies as heat sensitive liposomal formulation of doxorubicin. ThermoDox is being evaluated in combination with radiofrequency ablation, that’s RFA in a global multi-center pivotal Phase 3 study of the largest unmet medical need remaining an oncology and that’s hepatocellular carcinoma also known as HCC primary liver cancer. We call our second and equally important platform TheraPlas. TheraPlas is short for therapeutic plasmids, as the name implies, this is nanoparticle based cell transfection technology has the ability to return DNA sequences, product for proteins with known anti-cancer properties, interactive agents for sustained local cellular production of the biologic for which its programmed. Our first candidate on this platform is an immunotherapy that we call GEN-1. GEN-1 actually is the production of the highly effected inflammatory protein of cytokine interleukin 12. IL-12 is well known to actively recruit the entirety of the body's immune system to work against deadly cancers. GEN-1 has been recently evaluated in a Phase I study and newly diagnosed Phase III and Phase IV ovarian cancer patients. And as we announced yesterday evening, based on highly encouraging data, we are now moving forward with randomized Phase I/II study in this very patient population. So, in summary there’s two platform technologies, two drug candidates, one in Phase III and one non-moving to Phase II rapidly, both showing very promise, and at chemotherapy, representing the legacy of medicine with an innovative means to improve both safety and efficacy and that's the holy grail of oncology folks. They evaluated in the largest unmet medical need in oncology. And the second investigational product, this one in the future of medicine, immunotherapy, showing some remarkable potential ovarian cancer, malignancy that effects the lives of over 200,000 women annually. Our goals as we’ve communicated over the past conference calls remain unchanged and that has been successfully completed the development of these novel innovated pharmaceutical elegant solutions to some cancers made difficult challenges, and if we are right, even Gen-1 are successful, the development of one if not two of the most important medicines in a generation. The Celsion conference call in the August we have announced several important milestones that continue to drive momentum both in and outside of the clinic and I wanted to touch on those. First on the financial side. Our balance sheet is strong. For the past four months we've significantly improved our cash balance. We announced several equity capital initiatives totaling almost $28 million, then we did some of the most non-diluted fashions available to us. Our cash position now provides an operating long runway going to the second quarter of 2019. That means the company has sufficient capital to achieve the follow. First, and importantly is the full enrollment of around 550 subjects in the upcoming study here, pivotal Phase 3 study that we just spoke of ThermoDox in primary liver cancer, and we also within this cash runway we expect to provide results from the study, first pre-point in turn efficacy and analysis projected to appearing on the first quarter of 2019. Additionally, we will initiate a follow-on Phase I/II clinical study of GEN-1 as a [indiscernible] first line therapy for the treatment of newly diagnosed stage 3 and 4 ovarian cancer patients this quarter, fourth quarter of this year. Our target is to enroll approximately 50% of the 90 subjects by year end 2018. Again, within our current cash balance. And this will be an open label study and we’re also file periodic reporting throughout the conduct of the trial of the safety and clinical results. Second topic today is our R&D day, I want to remind you, I want to go over quickly, I want to remind you though that at October 12, we have an R&D day in your city, the goal of which is to provide investors and analysts with an update on our clinical programs that we just focused. If you go to our website, I believe you find the insights from the discussion to be invaluable as you assess Celsion’s long term potential. So briefly the OPTIMA study was discussed. The OPTIMA study clinical presenters representing multiple medical disciplines including hepatology, interventional radiology and surgery travel from regions where HCC is a significant health problem including South Korea, Philippines and regions in Europe, to discuss past and current experiences with ThermoDox for the treatment of HCC including and importantly representative case study. Dr. Borys provided the important data supporting the hypothesis from the study and moderated a panel discussion among these three investigators. With regards to GEN-1 the lead clinical investigator for the innovation study and then leading immuno-oncology experts from the Roswell Park Cancer Institute focused on the clinical and translational data from our recently completed Phase 1b study. And a copy of this presentation and the audio are on our website under News and Investors financial desk. I encourage all of you to take some time to listen and review the material. I think you will find it very insightful and instructive, as I said earlier as you consider long-term potential of associates and these two very important intriguing products. Our third topic today is ThermoDox in the Phase III OPTIMA Study. If you read our press release, we’re now 70% enrolled the Phase III OPTIMA Study is on track to complete its 550-patient subject recruitment. We’re on the middle of the next year. The study’s hypothesis is based on our substantive learning from a large sub group analysis of the prior week study, which I will remind you as you know minutes of PFS endpoint. While the hypothesis is supported with some of most persuasive and productive perspective and retrospective data that has ever been taken in my experience for clinical trial. Much of this data analysis ere included and accepted by peer review and recently published manuscript of the HEAT study in clinical cancer research. It’s a high impact medical journal. The lead author for this publication is Professor Tak, if you are interested in or planning to search for this article. In the article -- in the manuscript the authors conclude in the intermediate sized HCC combining Radiofrequency Ablation, RFA, conducted for a minimum of 45 minutes with ThermoDox is significant potential to dramatically improve overall survival it should be studied. I want to point out that the conclusions noted in the manuscript on either Arsenal or HEAT study manuscript authors alone. I will remind you that the National Institutes of Health conducted a completely independent analysis of the intent to treat population of all 447 single legions patients in the study and concluded that longer RFA heating times when combined more ThermoDox resulted in a statistically improvement in overall survival. Now this is not true of RFA alone. So, they looked at two cohorts RFA with ThermoDox and RFA alone and they concluded that when combining RFA or ThermoDox with RFA, the longer heating times resulted in a statically significant improvement in overall survival. This conclusion was presented at the RFA conference last December to a standing room only crowd. And I turn off with the NIH’s strongly supported this thesis in the follow-on OPTIMA study. And by the way the while analysis was conducted by NIH’s in the same population that’s currently being recruited and treated in the OPTIMA study. So now our highly de-risked, risked Phase III OPTIMA study of ThermoDox plus RFP standardized for 45 minutes in newly diagnosed HCC patients is on track and on budget. The guys report that all of the major costs and heavy lifting for this trial are now behind us. Additionally, on August 7, the OPTIMA study’s independent Data Monitoring Committee completed a pre-planned interim review of the first 275 or 50% of the patients randomized in the trial as of April 2017. Based on their assessment of safety, data quality, protocol compliance and trial risk, the DMC unanimously recommended that the study continue according to protocol to its final readout without revision. By the way also note that the data presented at the DMC indicated that there has been 99% plus compliance with minimum 45 minutes RFP heating time as required in the protocol. Also note that the 14 regulatory authorities across the globe including Europe, North America and Asia, in all major HCC markets have reviewed and approved the OPTIMA study protocol. We have engaged internationally recognized world-class CROs and data management teams to ensure good clinical practice, ICH compliance, protocol adherence, and high quality data analytics and we have a proven and highly reliable supply chain with not one, not two, but three redundant contract manufacturing organizations, that’s CMO, who are registered and capable of producing ThermoDox in all regions of the world, providing a cost structure that ALBA guarantees high gross margins, regardless of the country or the local economy. I would also summit that with little, if any operational risk and all the major costs behind us via OPTIMA study, as we now see it is we’re now beginning to look forward to study completion and data readout. If you believe the many analyses supporting the OPTIMA study, some which I just talked about, including an independent analysis of overall survival conducted by the NIH, then you have to agree that our chances of success here are very good. In addition to maintaining our focus on high quality, execution of the study, we have also paid attention to the enormous commercial opportunity for ThermoDox, which is led by our regulatory strategy as follows. ThermoDox has received FDA Fast Track Designation which provides among other things priority review. ThermoDox has been granted orphan drug designation for primary liver cancer in both the U.S. and Europe, which extents market exclusivity for seven years and 10 years, respectively, in these major revenue markets. Based on prior discussions and subject to a successful trial, we have designed the OPTIMA study to enroll sufficient number of patients from each ethnicity or country to support registrational filings in the U.S., Europe, China, South Korea, Taiwan and Vietnam. Additionally, the CFDA, that’s China FDA informed Celsion that if the ongoing Phase III OPTIMA study successful the trial could serve as the basis for direct regulatory filing in China without the need to file for prior approval in the U.S. or Europe, which is currently required to foreign company applications. This would allow Celsion to accelerate this plans for regulatory filing in China and if approved, provide a significant lead earlier launch date in China than originally expected. China as you know represents or as perhaps the most significant market opportunity for ThermoDox globally and is approximately 50% of the over 850,000 new cases diagnosed each year originated in China. In this market the largest future market for pharmaceuticals in the world I believe it safe to say that we are well positioned. Our fourth topic this morning is GEN-1 our marvelous entry into immunotherapy. GEN-1 our immune-oncology candidate developed in our fair [indiscernible] technology platform as I discussed is a gene mediated immunotherapeutic which recruits the body entire immune system to fight malignancies. GEN-1's active agent is a DNA plasmid coded for the cytokine interleukin IL-12, as we discussed the IL-12 plasma is incorporated into our proprietary non-viral nanoparticle delivery system. When administered locally into a body cavity like the peritoneum in bladder, or even a cavity created by surgical removal of tumor mass. The nonoparticles invade surrounding cells and takeover the metabolic machinery turning each cell into mini factory for local sustained production of the IL-12 protein. The first indication of when we're studying for GEN-1 is ovarian cancer. The patients newly diagnosed with this cancer there is less than 45% chance of surviving 5 years. While major reason of diagnosis is made the patients have advanced disease have stages 3 and 4. When the cancer is spread, the previous clinical trials in this patient population GEN-1 has been used either as a monotherapy or a combination with chemotherapy and has shown promising results. most importantly GEN-1 has shown clear signs of biological activity and early signs of clinical benefit in our recently completed Phase 1b dose escalation trial that we called the OVATION study. The OVATION study evaluated GEN-1 plus [indiscernible] and chemotherapy followed by debulking surgery in newly diagnosed stage 3 and 4 ovarian cancer patients. Prior to debulking, our patients were treated with what the three cycles of platinum and taxane the goal of which was to improve surgical outcome by shrinking the tumor mass. To this regimen we added eight weekly cycles of GEN-1. We reported that GEN-1 plus new regimen chemotherapy produced positive clinical results with no dose limiting toxicities and promising dose -- and efficacy signals. In the first 14 patients treated in this study there has been 100% disease control rate, 86% objective response rate, 2 complete responses and 100% overall response rate according to resist criteria at the highest dose. Then of the 14 surgically receipted outpatients, 5 patients had successful reception of their tumors, one patient demonstrated complete cytological response at some PCR, 64% of patients had an entire zero that's a margin negative reception and 100% or zero receptions were observed at the highest dose. Additionally, the per protocol treatment group's exceeding expectations with greater than 13 months PFS and going strong. We also reported the following translation of research findings from the available patients in the OVATION study. All 15 patients in this study showed greater than 90% drop in the CA125 levels, I'll remind that a 50% drop is considered to be clinically significant. And the ratio of CD8 cells to immunosuppressive cells has increased in approximately 75% of patients suggesting an overall shift in the tumor microenvironment from suppressive to pro-immune stimulatory. The data shown that production of therapeutic IL-12 interferon-gamma and VEGF levels in those patient population are dose related and more predominantly [indiscernible] flow are no changes in patient’s blood samples. Most importantly these distinct immunological changes in the local disease environment appear translate into clinical benefit and want to continue development of our GEN-1 IL-12 immunotherapy is a potential combination in both first and second line of ovarian cancer. These data along with dose and safety analyses were presented to medical experts KOLs and our medical advisory board on September 27 of this year. Last Friday, as you all know in our press release we filed for 90 patient open label randomized Phase I/II protocol to evaluate GEN-1 in this say newly diagnosed ovarian cancer patient population. The treatment protocol is almost exactly the same as the prior Phase Ib OVATION study with one major addition. And that is following debulking surgery, patients will continue to receive interferon doses of GEN-1 for two months. Our hypothesis is that continuous stimulation of the immune system after surgery that further provide a beneficial effect attacking cancer progression. Phase 1/II study will begin with a Phase I dose escalating run to as attain whether higher dose of GEN-1 is both safe and active. As we reported earlier we are not saying any dose limiting toxicities in our prior Phase 1b OVATION study, however we also drove most promising efficacy signals were at the highest dose. So, it’s clear that next higher dose should be evaluated prior to moving on to the Phase II portion of the study. So, after the Phase 1 portion of the study is completed, we’ll issue an open label study of approximately 90 newly diagnosed Stage 3 and 4 ovarian cancer patients, which will allow for periodic reporting of results throughout the clinical trial. We expect there are several clinical announcements from this study during 2018 and 2019. And now I’m going to move on to our fifth and the final point before I turn the call over to Jeff. And that’s our financial strength and our lean cost structure. Let me just start by saying our organization structure is lean. Our spending is highly efficient and very predictable. We continue to offering with the very small staff of less than 20 employees supplemented our highly professional contract research organizations. Our future spending on average will be approximately $1.3 million per month. That’s approximately $15 million to $16 million per year to conduct two major clinical trials of global Phase III pivotal trial in primary liver cancer and advance clinical trials in newly diagnosed ovarian cancer. In recent camp raised in October, we are in an extraordinarily strong financial position, our cash run rate will curious long for the second quarter of 2019. So, with that, I will turn now to the call over to Jeff for a review of our recent financing activities in 2017 and our third quarter financial results. Jeff?
